In April 2026 the FDA approved a GLP-1 you swallow instead of inject, with no fasting or water rules attached. Here's what the trial that got it approved actually found — and how it stacks up against the pens and pills already on the market.
Foundayo (orforglipron) is a once-daily tablet that the FDA approved on April 1, 2026 for adults with obesity, or with overweight plus a weight-related condition. It works on the same GLP-1 receptor as semaglutide and tirzepatide, but it's built differently: instead of a peptide that has to be injected or absorbed under strict fasting conditions, orforglipron is a small molecule — chemically closer to an ordinary pill than to a protein-based drug.
That matters practically. Novo Nordisk's existing oral semaglutide pill (Rybelsus) has to be taken first thing in the morning on an empty stomach, with no more than a few ounces of water, then followed by a 30-minute wait before eating or taking anything else. Foundayo carries none of those restrictions — Lilly's own labeling says it can be taken any time of day, with or without food or water, which is the headline feature distinguishing it from every other oral GLP-1 option.
Approval rested on the ATTAIN Phase 3 program — more than 4,500 people with obesity or overweight across two global trials. ATTAIN-1 randomized 3,127 adults without diabetes to placebo or one of three orforglipron doses for 72 weeks. Weight loss rose with dose, and every dose beat placebo by a wide margin:
Among people who stayed on the highest dose for the full 72 weeks, average loss reached 12.4% (about 27.3 lbs), versus 0.9% on placebo. Counting everyone regardless of adherence — a more real-world number — the highest-dose group averaged 11.1% (about 25 lbs).
GI side effects looked like every other drug in the class — nausea, constipation, diarrhea, vomiting — and discontinuation from side effects rose with dose: 5.1% at 6 mg, 7.7% at 12 mg, and 10.3% at 36 mg stopped due to adverse events, versus 2.6% on placebo.
Sources: Eli Lilly and Company, FDA approval announcement, April 1, 2026 — investor.lilly.com. Full ATTAIN-1 trial results: Wharton et al., NEJM 2025 — nejm.org.
Foundayo's weight-loss numbers at its highest dose land below tirzepatide's (SURMOUNT-1 showed roughly 22.5% at 15 mg) and roughly in line with semaglutide's injectable results. Its main advantage isn't a bigger effect — it's the format: no needle, no pen storage, no clinic visit for training, and none of the meal-timing rules that make Rybelsus awkward to fit into a normal morning.
Like every GLP-1 medicine, Foundayo carries a boxed warning about thyroid C-cell tumors seen in rodent studies, and it isn't recommended alongside another GLP-1 drug. It also isn't a swap-in replacement for injectable therapy without a prescriber's guidance — dose equivalence between the drug classes hasn't been established.
This article summarizes Eli Lilly's April 2026 FDA approval announcement and the published ATTAIN-1 trial results for general education. It is not medical advice. Talk to your prescriber before starting, stopping, or switching any GLP-1 medication.